AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.
AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.
ViiV’s Cabotegravir Beats Out Gilead’s Truvada for Preventing HIV in Women
Blockbusters, Clinical Data, Clinical Trials, HIV Prevention, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health, R&D, Shareholders, The Bill and Melinda Gates Foundation, Therapeutics, WomenViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
FDA Declines Review of Bristol Myers Squibb and bluebird’s Multiple Myeloma Therapy
B-cell maturation antigen (BCMA), Biologics License Application (BLA), Business, CAR-T Therapy, Collaborations, FDA, FDA/Regulatory, Immunotherapies, Investors, Refusal to File letter, Relapse/Refractory Multiple Myeloma, Shareholders, SharesShares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
Bristol-Myers Squibb’s shareholders voted to approve the drugmaker’s $74 billion takeover of Celgene despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.
Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.